Erasca (ERAS)

• Market cap: $672M
• 1 day: -2.87%
• 5 days: 3.95%
• 1 month: 12.32%
• 3 months: 52.9%
• 6 months: 65.73%
• Year to date: -12.22%
• 1 year: -15.36%
• 5 years: -86.4%
• 10 years: -86.4%
• Sector: Healthcare
• Industry: Biotechnology

About: Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.

Employees: 129